Key clinical point: Higher serial platelets were associated with overall survival of invasive aspergillus; galactomannan trends were linked to treatment response.
Major finding: Every 10 X109/L platelet count increase at week 2 and 4 improved 12-week survival odds by 6%-18%.
Study details: Post hoc analyses were performed on two multicenter, randomized, antifungal clinical studies.
Disclosures: The study was supported by the National Medical Research Council, Singapore. The two clinical studies analyzed were funded by Pfizer. The authors reported relationships with a number of pharmaceutical companies.
L.Y.A. Chai, et al. Clin Microbiol Infect 2019; doi10.1016/j.cmi.2019.10.019.